<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05004246</url>
  </required_header>
  <id_info>
    <org_study_id>TJ20210622</org_study_id>
    <nct_id>NCT05004246</nct_id>
  </id_info>
  <brief_title>Longitudinal Changes in Characteristics of COVID-19 Survivors and Their Long-term Follow-up Study</brief_title>
  <official_title>Longitudinal Changes in Characteristics of COVID-19 Survivors and Their Long-term Follow-up Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tongji Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>First Affiliated Hospital Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yichang Central Hospital.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Wenzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shiyan Renmin Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The second Hospital of JingZhou</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yunnan Provincial Infectious Disease Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>WUHAN Number Seven HOSPITAL</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanxi Bethune Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tongji Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Follow-up study of Coronavirus disease 2019 (COVID-19) survivors has rarely been reported. We&#xD;
      aimed to investigate longitudinal changes in the characteristics of COVID-19 survivors after&#xD;
      discharge.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      From December 2019, coronavirus disease 2019 (COVID-19), caused by a β-coronavirus known as&#xD;
      severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread across the globe.&#xD;
      Numerous studies have been performed so far to investigate clinical characteristics, risk&#xD;
      factors, potential treatment and pathogenesis of COVID-19. However, little information is&#xD;
      available on the long-term prognosis and possible sequelae of COVID-19 survivors who have&#xD;
      recovered and been discharged from hospital. Hence, the investigators conducted a prospective&#xD;
      study to investigate the long-time prognosis and the possible sequelae of COVID-19 survivors.&#xD;
      The investigators evaluated Demographic and clinical characteristics, laboratory and&#xD;
      radiological findings,pulmonary function tests, electrocardiogram, complications as well as&#xD;
      treatment and symptoms and signs of COVID-19 patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 15, 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>symptoms and signs</measure>
    <time_frame>1-3years</time_frame>
    <description>symptoms and signs will be collected.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>1-3years</time_frame>
    <description>Quality of Life will be assesed using the MOS item short from health survey（SF-36.Minimum value:0, Maximum value: 100. Higher scores mean a better outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mental quality</measure>
    <time_frame>1-3years</time_frame>
    <description>Mental quality will be assessed using hospital anxiety and depression scale.Minimum value:0, Maximum value: 21. Higher scores mean a worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>laboratory findings,change from baseline for blood laboratory measures</measure>
    <time_frame>1-3years</time_frame>
    <description>the change from baseline for laboratory examination （Hb in g/L, Leukocyte in /L, neutrophil count in /L，lymphocyte count in /L，Platelet count in /L，Creatinine in μmol/L, Bilirubin in mg/dL, ALP in U/L, γ-glutamyl transpeptidase in U/L，AST in U/L, ALT in U/L, Albumin in g/dL, triglycerides in mmol/L, total cholesterol in mmol/L，cardiac troponin I in ng/mL， myoglobin in ng/mL， brain natriuretic peptide precursors in pg/mL， lactate dehydrogenase in U/L, Creatine Kinase in U/L).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Radiological findings</measure>
    <time_frame>1-3years</time_frame>
    <description>Radiological findings such as chest computed tomography will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>pulmonary function</measure>
    <time_frame>1-3years</time_frame>
    <description>pulmonary function tests will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart function</measure>
    <time_frame>1-3years</time_frame>
    <description>electrocardiogram including arrhythmia,ST-T change and conduction block will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Abdominal ultrasound</measure>
    <time_frame>1-3years</time_frame>
    <description>Abdominal ultrasound will be assessed.</description>
  </primary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Prognosis</condition>
  <condition>Sequelae</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      peripheral blood mononuclear cell (PBMC)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        This study will enroll recovered patients with confirmed COVID-19 who were discharged from&#xD;
        Hospital.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients with confirmed COVID-19 who have complete hospitalization data.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Suspected cases of COVID-19.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Qin Ning, MD.,PhD.</last_name>
    <phone>+8602783662391</phone>
    <email>qning@vip.sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of infectious disease, Tongji Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qin Ning</last_name>
      <phone>+8602783662391</phone>
      <email>qning@vip.sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>July 21, 2021</study_first_submitted>
  <study_first_submitted_qc>August 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2021</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tongji Hospital</investigator_affiliation>
    <investigator_full_name>Qin Ning</investigator_full_name>
    <investigator_title>Director of Department of Infectious Diseases</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>follow-up</keyword>
  <keyword>consequences</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

